Article
Universal protection of allogeneic cell therapies from natural killer cells via CD300a agonism
2024-05-07
Abstract excerpt
Immunogenicity limits the persistence of off-the-shelf, allogeneic cell therapies and transplants. While ablation of human leukocyte antigen (HLA) removes most T cell and humoral alloreactivity, no solution has enabled universal protection against the resulting natural killer (NK) cell response. Here, we engineered Trans Antigen Signaling Receptors (TASR) as a new class of NK inhibitory ligands and discovered CD30...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- fbc6c641-3729-5c48-a293-1853394596f9
- DOI
- 10.1101/2024.05.05.592600
